Should HEXO (TSX:HEXO) Stock Be on Your Contrarian Buy List?

Is HEXO (TSX:HEXO) now oversold?

| More on:
question marks written reminders tickets

Image source: Getty Images

Marijuana stocks took a big hit in the second half of 2019 and the cannabis sector continues to struggle as we begin 2020.

HEXO (TSX:HEXO)(NYSE:HEXO) has really taken a hit, falling from $11 per share last April to a below $2. At the time of writing HEXO trades at $1.80 and has a market capitalization of about $450 million.

Let’s take a look the reasons for the rout and try to determine whether HEXO deserves to be a contrarian buy for your portfolio today.

Industry woes

Investors piled into pot stocks ahead of the launch of the recreational market in October 2018 with high hopes for the industry. The initial rollout didn’t go as planned, with supply shortages and distribution challenges hampering sales and frustrating potential customers.

The sector caught a second wind, however, in the first four months of 2019. The rebound in the share prices of the cannabis companies came as part of an overall recovery in equity markets.

Renewed enthusiasm about sales for the year also helped bring investors back into the sector, and some had an eye on getting in ahead of the launch of the second phase of Canada’s recreational pot legalization.

Unfortunately, the quarterly reports coming from the cannabis producers started to indicate that challenges remained. Revenue growth began to stall out, while expenses and losses moved steadily higher. This made investors question their appetite for holding stocks with such lofty valuations.

In addition, the industry started to lose credibility as reports emerged that some companies were not following the rules. Production in non-licensed facilities and accusations of self-dealing by some industry executives gave investors and lenders another reason to take a step back.

HEXO’s issues

HEXO’s trouble began with its acquisition of Newstrike Brands in the first part of 2019. The deal was initially viewed as positive for HEXO as it expanded the company’s licensing reach to eight provinces and added important production capacity and new brands to the portfolio.

At the time of the deal, HEXO said fiscal 2020 revenue could hit $400 million. In June, the company maintained the optimistic guidance, even saying that it expected its fiscal Q4 2019 revenue, which covered the three months that ended July 31, to be close to $26 million, or about double the previous quarter.

In October, the management team stepped back the guidance and painted a very different outlook for the 2020 fiscal year. HEXO cut 200 jobs and shut down a former Newstrike production site. When the fiscal Q4 2019 results actually came out, net revenue was just $15.4 million.

The fiscal Q1 2020 report, showed net revenue of $14.5 million and a net loss of $62.4 million. On an annualized basis projected fiscal 2020 revenue at the same rate would be less than $60 million, well off the $400 million the company anticipated just six months ago.

HEXO recently raised US$25 million through a share issue at US$1.67 per share. This followed a $70 million loan provided to the company by a group that primarily consisted of HEXO executives and board members.

Should you buy HEXO?

Given the ongoing high level of cash burn, investors should be careful. Revenue would have to pick up considerably to get the company to profitability and enable HEXO to start to attract new investors.

The recent launch of the edibles and drinks market could provide the revenue surge HEXO needs, but the early indication is that the market is adopting a wait-and-see approach.

The stock could certainly rally on reports of better-than-expected revenue in the coming quarters. Any rumours of a takeover could also drive the share price higher.

At this point, however, I would probably search for other opportunities.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »